Trastuzumab Not Yet Recruiting Phase 2 Trials for Leptomeningeal Disease / Metastatic Breast Cancer (MBC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03501979Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD